SOURCE: annual_report_text (1).txt
CHUNK: 537 of 1106
SIZE: 613 characters
PREVIOUS: chunk_0536_annual_report_text (1).txt
NEXT: chunk_0538_annual_report_text (1).txt
------------------------------
compared to EUR 46.4 
million per December 31, 2022. These intangible 
assets relate mainly to: Research and Development costs for EUR 
57.7 million. The net amount is higher 
because of the change in Depreciation (cf. next paragraph) and the increased spend 
compared to 2022. Intangible assets under construction for a 
net worth of EUR 9.0 million which includes 
development costs related to Product 
Lifecycle Management and the EU Medical 
Device Regulation. In accordance with the Royal Decree of 
December 15, 2015, research costs have been 
capitalized and amortized over the year since 
January 1, 2016.